195 related articles for article (PubMed ID: 35086148)
1. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort.
Blondon M; Bodmer A; Thouvenin L; Lecompte T; Righini M; Fontana P; Casini A
Blood Adv; 2022 May; 6(9):2884-2892. PubMed ID: 35086148
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
Faiz AS; Guo S; Kaveney A; Philipp CS
Blood Coagul Fibrinolysis; 2021 Sep; 32(6):373-381. PubMed ID: 33973894
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic imbalance induced by tamoxifen in estrogen receptor-positive breast cancer patients: An observational study.
Didembourg M; Reda S; Oldenburg J; Rühl H; Douxfils J; Morimont L
Int J Lab Hematol; 2024 Jun; 46(3):546-554. PubMed ID: 38296772
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
7. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
Orsi FA; Biedermann JS; Kruip MJHA; van der Meer FJ; Rosendaal FR; van Hylckama Vlieg A; Bos MHA; Leebeek FWG; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2019 Feb; 17(2):319-328. PubMed ID: 30565854
[TBL] [Abstract][Full Text] [Related]
10. Risk-reducing medications for primary breast cancer: a network meta-analysis.
Mocellin S; Goodwin A; Pasquali S
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012191. PubMed ID: 31032883
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
Yu Q; Xu Y; Yu E; Zheng Z
J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
[TBL] [Abstract][Full Text] [Related]
12. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
14. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
[TBL] [Abstract][Full Text] [Related]
15. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
16. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
17. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen induces resistance to activated protein C.
Rühl H; Schröder L; Müller J; Fimmers R; Sukhitashvili S; Welz J; Kuhn WC; Oldenburg J; Rudlowski C; Pötzsch B
Thromb Res; 2014 May; 133(5):886-91. PubMed ID: 24568775
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
